InnoCare Pharma's September report shows stable share capital

InnoCare Pharma Limited, listed on the Hong Kong Exchanges and Clearing Limited, submitted its monthly return for the period ended September 30, 2025. The company's authorised/registered share capital remained at 25,000,000,000 ordinary shares with a par value of $0.000002 per share, totaling $50,000. There were no increases or decreases in this capital during the month.

For its ordinary shares listed on HKEX, the number of issued shares (excluding treasury shares) stood at 1,494,598,235, with 1,686,000 treasury shares, resulting in a total of 1,496,284,235 issued shares. Similarly, ordinary shares listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange maintained 268,359,717 issued shares (excluding treasury shares) and no treasury shares. The report indicates no movement in either issued shares or treasury shares across all classes for the reported month.

The company also detailed its 2023 and 2024 RMB Share Incentive Schemes, with 4,560,750 shares under the 2023 scheme and 9,750,200 shares under the 2024 scheme remaining available for issuance or transfer as of month-end. As of September 2025, a total of 673,750 Restricted Shares from the 2023 scheme and 120,000 Restricted Shares from the 2024 scheme have lapsed.